Shree Ganesh Remedies Ltd Valuation Shifts Signal Renewed Price Attractiveness

Valuation Metrics Reflect Changing Perceptions

As of 24 March 2026, Shree Ganesh Remedies trades at ₹467.20, down 3.48% from the previous close of ₹484.05. The stock’s 52-week range spans from ₹381.10 to ₹828.00, indicating significant volatility over the past year. The company’s P/E ratio currently stands at 33.16, a figure that has moderated enough to shift its valuation grade from expensive to fair. This adjustment is significant given the pharmaceutical sector’s typical valuation range and the company’s historical multiples.

Complementing the P/E ratio, the price-to-book value ratio is 3.91, which also aligns with the fair valuation classification. These metrics suggest that while the stock is no longer considered overvalued, it remains priced at a premium relative to book value, reflecting investor confidence in the company’s asset utilisation and growth prospects.

Comparative Analysis with Industry Peers

When benchmarked against key competitors in the Pharmaceuticals & Biotechnology sector, Shree Ganesh Remedies’ valuation appears more balanced. For instance, Bliss GVS Pharma, a peer with a fair valuation grade, trades at a P/E of 18.58 and an EV/EBITDA of 13.56, both considerably lower than Shree Ganesh Remedies’ P/E of 33.12 and EV/EBITDA of 18.00. Conversely, companies like Shukra Pharma and NGL Fine Chem remain very expensive, with P/E ratios of 53.5 and 36.45 respectively, and EV/EBITDA multiples well above 20, underscoring the relative attractiveness of Shree Ganesh Remedies’ current valuation.

Other peers such as Kwality Pharma and Hester Bios also maintain expensive valuations, with P/E ratios of 26.44 and 27.83 respectively, but still below Shree Ganesh Remedies’ level. This positioning suggests that while the stock is not the cheapest in the sector, it offers a more reasonable entry point compared to some of the highly priced competitors.

Financial Performance and Return Metrics

Shree Ganesh Remedies’ return profile over various time horizons presents a mixed picture. The stock has outperformed the Sensex over the medium to long term, delivering a 92.78% return over three years and an impressive 111.32% over five years, compared to the Sensex’s 25.50% and 45.24% respectively. However, recent performance has been lacklustre, with a 34.66% decline over the past year against a 5.47% drop in the Sensex, and a modest 0.86% gain year-to-date compared to the Sensex’s 14.70% loss.

This divergence highlights the stock’s volatility and sensitivity to sector-specific and company-level developments. The recent downward pressure on the share price, reflected in today’s trading range of ₹451.05 to ₹479.85, underscores investor caution amid broader market uncertainties.

Profitability and Efficiency Indicators

From an operational standpoint, Shree Ganesh Remedies exhibits solid profitability metrics. The latest return on capital employed (ROCE) stands at 16.87%, signalling efficient use of capital to generate earnings. Return on equity (ROE) is also respectable at 11.79%, indicating reasonable returns for shareholders despite the micro-cap status of the company.

Enterprise value multiples further contextualise the valuation. The EV/EBIT ratio is 25.75, while EV/EBITDA is 18.00, both suggesting that the market is pricing in growth potential but with a cautious stance. The EV to capital employed ratio of 3.83 and EV to sales of 6.00 reinforce the notion that the stock is fairly valued relative to its operational scale and earnings before interest and taxes.

Valuation Grade and Market Sentiment

MarketsMOJO’s recent upgrade of Shree Ganesh Remedies’ valuation grade from expensive to fair on 12 January 2026 reflects a recalibration of market sentiment. Despite this, the overall Mojo Score remains low at 28.0, with a Strong Sell grade, downgraded from Sell. This suggests that while valuation metrics have improved, other fundamental or momentum factors may be weighing on the stock’s outlook.

The micro-cap classification further adds to the risk profile, as liquidity and volatility concerns typically accompany smaller market capitalisations. Investors should weigh these factors carefully against the company’s growth prospects and sector dynamics.

Contextualising Price Attractiveness

In the context of the broader Pharmaceuticals & Biotechnology sector, Shree Ganesh Remedies’ current valuation metrics position it as a moderately attractive option for investors seeking exposure to micro-cap opportunities. Its P/E ratio of 33.16, while higher than some peers, is justified by its robust ROCE and ROE figures, which indicate operational efficiency and shareholder value creation.

However, the zero PEG ratio signals a lack of meaningful earnings growth expectations embedded in the price, which may temper enthusiasm among growth-focused investors. The absence of a dividend yield further emphasises the company’s reinvestment strategy or cash flow constraints, factors that investors must consider in their valuation assessments.

Investor Takeaway

For investors analysing Shree Ganesh Remedies Ltd, the shift from expensive to fair valuation grades offers a window of opportunity to reassess the stock’s potential. While the Strong Sell Mojo Grade advises caution, the company’s valuation relative to peers and historical levels suggests that the downside risk may be partially priced in.

Given the stock’s mixed recent performance and micro-cap status, a balanced approach is prudent. Investors should monitor upcoming earnings releases, sector developments, and any changes in the company’s operational metrics to better gauge the sustainability of its valuation levels.

Ultimately, Shree Ganesh Remedies presents a nuanced investment case where valuation improvements coexist with fundamental challenges, underscoring the importance of comprehensive analysis before committing capital.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →